Parkinson's disease

R&D

pharmaphorum podcast Episode 209a, Gene Mack

Allosteric small molecule therapies in PD, with Gene Mack

pharmaphorum looks back to a conversation with Gain Therapeutics' CEO Gene Mack earlier in the year, on research in the Parkinson's disease space.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

R&D

The importance of time: Grifols seeks biomarkers for early d...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J.

News

plasma test tubes being placed by a gloved hand in a lab

Grifols gets $21m award for Parkinson's biomarker hunt

Grifols has been awarded a $21m grant from the Michael J Fox Foundation to find plasma biomarkers to predict Parkinson's years before symptoms start.

News

Bayer gains ground in two-fronted Parkinson's offensive

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

Allosteric small molecule therapies in PD, with Gene Mack

Bayer starts pivotal Parkinson's cell therapy trial

NRG raises £50m to start trials of Parkinson's, ALS drug

The importance of time: Grifols seeks biomarkers for early d...

Grifols gets $21m award for Parkinson's biomarker hunt

Bayer gains ground in two-fronted Parkinson's offensive

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Parkinson's disease

Editor's Picks